摘要
目的观察老年肥胖2型糖尿病(T2DM)患者使用格列美脲联合诺和锐30的临床疗效。方法将血糖控制不佳的36例使用诺和锐30联合二甲双胍和吡格列酮治疗的老年肥胖T2DM患者随机分为2组,治疗组在继续调整诺和锐30的基础上加用格列美脲,对照组单纯调整诺和锐30的剂量,进行12周的临床观察。结果在治疗12周后,2组的糖化血红蛋白(HbA1c)及空腹血糖、餐后血糖均明显下降,治疗组下降更为明显(P<0.05);治疗组的体质量指数(BMI)及胰岛素用量较对照组均显著降低(P<0.05)。结论对于血糖控制不佳的老年肥胖T2DM患者,格列美脲联合诺和锐30可以有效降低患者血糖水平,同时可显著减少胰岛素用量,而且对控制体质量起到有益作用。
Objective To observe the clinical efficacy of glimepiride combined with aspart 30 on type 2 diabetes mellitus complicated with obese in the elderly. Methods Thirty-six aged obese patients with type 2 diabetes mellitus who received the treatment of aspart 30 combined with metformin or pioglitazone with terrible efficacy were randomly divided into control group and therapy group (receiving aspart 30 combined with glimepiride) for 12 weeks. Results The levels of glycosylated hemoglobin (HbA1c),fasting blood glucose (FBG),2-hour postprandial blood glucose(2hBG) of both groups were significantly decreased, and the decrease was more obvious in the therapy group(P<0.05).Moreover,there was significant decrease in the levels of BMI and daily insulin dose in the therapy group(P<0.05). Conclusions For aged obese type 2 diabetic patients, aspart 30 combined with glimepiride could efficiently decrease blood glucose and insulin dosage, and may play a role in controlling weight.
出处
《实用老年医学》
CAS
2013年第2期135-137,共3页
Practical Geriatrics
关键词
格列美脲
诺和锐
肥胖
型糖尿病
glimepiride
aspart 30
obese
type 2 diabetes mellitus
